Cardea Bio Revenue and Competitors

Location

$22.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cardea Bio's estimated annual revenue is currently $1.2M per year.(i)
  • Cardea Bio's estimated revenue per employee is $77,500
  • Cardea Bio's total funding is $22.9M.

Employee Data

  • Cardea Bio has 16 Employees.(i)
  • Cardea Bio grew their employee count by -48% last year.

Cardea Bio's People

NameTitleEmail/Phone
1
Controller & Director FinanceReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Chief Business OfficerReveal Email/Phone
4
Senior Director, Multiomics Assay DevelopmentReveal Email/Phone
5
Senior Director, Manufacturing and Supply ChainReveal Email/Phone
6
Project Manager | Production Engineer & SupervisorReveal Email/Phone
7
Production Team Member, Graphene TransferReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Cardea Bio?

Cardea is developing a Tech+Bio Infrastructure based on proprietary Biology-gated Transistors, or Cardean Transistors. Cardean Transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with live-streams of multi-omics signal analysis. Until now, life science data was comprised of static snapshot datasets. Cardea uses Cardean Transistors to build chipsets that can be integrated into thousands of “Powered by Cardea” products and applications with features never before seen. Together with their Innovation Partners, Cardea can link biology to computers and measure real-time biological signals - allowing for a new generation of applications Linking up to Life. 

keywords:N/A

$22.9M

Total Funding

16

Number of Employees

$1.2M

Revenue (est)

-48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cardea Bio News

2022-03-30 - Cardea Bio Completes Planned Launch of CRISPR QC

This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit)...

2022-03-30 - Cardea Bio completes planned launch of CRISPR QC

Cardea Bio is the world's only mass producer of a biocompatible semiconductor, the BPU™ (Biosignal Processing Unit). The BPU is the first and...

2021-01-12 - Cardea Bio Takes In $6.5M More In Series A

San Diego-based Cardea Bio, a startup that is developing molecular biology equipment which uses semiconductors to analyze samples, said on Tuesday that it has raised $6.5M more in its Series A funding. The company said the new funding was led by 3E Bioventures Capital, and also included existing ...

2019-03-22 - Cardea Bio Gets $7.8M For Biosensors

San Diego-based Cardea Bio, a manufacturer of graphene-based, digital biosensors being used to monitor biological systems using semiconductors, announced this morning that it has raised $7.8M in a Series A-1 financing round. The financing was led by Alexandria Venture Investments, and also inclu ...

2019-03-22 - Cardea Bio Raises $7.8M Series A-1 Financing

Cardea Bio Inc., a San Diego, CA-based commercial manufacturer of the biology-enabled transistor technology made from graphene-based biosensors, raised $7.8m Series A-1 financing. The round was led by Alexandria Venture Investments, with participation from new and existing investors, including ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.4M16N/AN/A
#2
$1.4M16N/AN/A
#3
$1.4M16N/AN/A
#4
$1.4M167%N/A
#5
$4M160%N/A